LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules
Correlate performance of LungLB Test with outcome of a scheduled biopsy.
Checked against the public recordLast updated Jun 13, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- LungLife AI
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. At least 18 years old with a CT identified indeterminate pulmonary nodule and scheduled for biopsy, at the time of consent. 2. Planned biopsy nodule of interest: 1. is solid ≤3 cm; or 2. is nonsolid, ground glass opacity, of any size; or 3. is part solid, where the solid component is no larger than 3cm (maximum diameter). Exclusion Criteria: 1. Current and or prior diagnosis +/- treatment of non-lung cancer within the past 3 years. 2. Current and or prior lung cancer diagnosis within 2 years following intent-to-cure surgery.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Clinical Site 04Los Angeles, California
- Clinical Site 05Bay Pines, Florida
- Clinical Site 03Miami, Florida
- Clinical Site 07Hines, Illinois
- Clinical Site 27Kansas City, Kansas
- Clinical Site 12Wichita, Kansas
- Clinical Site 08Kansas City, Missouri
- Clinical Site 18Reno, Nevada
- Clinical Site 01New York, New York
- Clinical Site 25Columbia, South Carolina
- Clinical Site 02Houston, Texas
- Clinical Site 32Milwaukee, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 13, 2024. Always confirm current availability with the study team.